Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants With Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial

OBJECTIVE: Nonalcoholic fatty liver disease (NAFLD) is a liver phenotype of type 2 diabetes and obesity. Currently, the efficacy of sodium–glucose cotransporter 2 (SGLT2) inhibitors and sulfonylureas in liver pathology and hepatic gene expression profiles for type 2 diabetes with NAFLD are unknown....

Descripción completa

Detalles Bibliográficos
Autores principales: Takeshita, Yumie, Honda, Masao, Harada, Kenichi, Kita, Yuki, Takata, Noboru, Tsujiguchi, Hiromasa, Tanaka, Takeo, Goto, Hisanori, Nakano, Yujiro, Iida, Noriho, Arai, Kuniaki, Yamashita, Tatsuya, Mizukoshi, Eishiro, Nakamura, Hiroyuki, Kaneko, Shuichi, Takamura, Toshinari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2022
Materias:
Emerging Therapies: Drugs and Regimens
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472500/
https://www.ncbi.nlm.nih.gov/pubmed/35894933
http://dx.doi.org/10.2337/dc21-2049

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472500/
https://www.ncbi.nlm.nih.gov/pubmed/35894933
http://dx.doi.org/10.2337/dc21-2049

Ejemplares similares